Our work provides evidence that rAAV-CRISPRa therapy during early adolescence can boost the expression of healthy Rai1 allele and modify disease progression in a mouse model of Smith-Magenis syndrome. This evidence concerns the gene RAI1 and Smith-Magenis syndrome.